Recent Company News

• 01:35 AM ET Jun 19, 2026
  

  Sumitomo Pharma, Novo Nordisk Pharma receive Japan MHLW additional indication approval for wegovy subcutaneous injection (¥1453.0000, -72)

• 11:04 PM ET Jun 07, 2026
  

  StreetAccount Summary - Trading higher/lower: Japan mid-day

• 07:53 PM ET Jun 15, 2026
  

  Sumitomo Pharma reports 'encouraging' new clinical and translational research presented at European Hematology Association (¥1418.5000, 0)

• 05:04 AM ET Jun 15, 2026
  

  Sumitomo Pharma upgraded to 1-outperform from 2-neutral at SMBC Nikko (¥1418.5000, 0)

• 10:43 PM ET Jun 09, 2026
  

  Sumitomo Pharma completes enrollment of patients in phase 2 study of Enzomenib (¥1425.0000, -37)

• 11:04 PM ET Jun 07, 2026
  

  StreetAccount Summary - Trading higher/lower: Japon mi-séance

• 07:51 PM ET Jun 01, 2026
  

  Sumitomo Pharma presents first clinical data from phase 1/2 trial of SMP-3124LP at ASCO 2026

• 12:08 AM ET May 13, 2026
  

  Sumitomo Pharma reports Q4 core net income attributable (¥800M) vs year-ago ¥2.4B (¥1598.5000, -11)

• 06:52 PM ET May 07, 2026
  

  Sumitomo Pharma initiated neutral at BofA (¥1657.0000, 0)